CardioPrecision Ltd, the global leader in transcervical access for the treatment of structural heart disease and cardiothoracic intervention, announces CE Mark of CoreVista® Retractor.
The revolutionary CoreVista® suite of devices offers the surgeon a single use retractor to perform minimally invasive cardiothoracic surgery and intervention through a short incision in the skin crease of the neck. The retractor is programmed innovatively to illuminate different zones of the operative field with a set of integrated lights.
“We are very excited to have received CE mark approval for CoreVista® Retractor from the notified body BSI. It is another significant milestone achieved on the Company’s journey from concept to commercialisation.” said CardioPrecision Founder and Chief Executive Officer, Dr Ying Sutherland, PhD.
Mr Fraser Sutherland MD, Consultant Cardiac Surgeon at the West of Scotland National Heart and Lung Centre and Chief Medical Officer of CardioPrecision commented: “With the rapid progress of less invasive approaches in other clinical disciplines, cardiac surgery has long recognised an urgent and unmet need for innovation that will permit less invasive cardiac surgery to be performed routinely. CoreVista® technology and products have been developed to fill this ‘void’ and will undoubtedly deliver real benefits for patients, surgeons, and hospitals. Feedback from surgeons involved in the early clinical experience has been fantastic and we look forward to product launch.”
About CardioPrecision Ltd
CardioPrecision Ltd, based in Glasgow, UK is the global leader in transcervical access for the treatment of structural heart disease and cardiothoracic intervention. CardioPrecision’s CoreVista® Retractor and Accessories allows cardiothoracic surgery to be performed through a short incision in the skin crease of the neck. CardioPrecision is dedicated to making patients’ lives better through the development of innovative, less invasive access solutions for cardiothoracic surgery and cardiovascular intervention. For more information, visit www.cardioprecision.com
This news release includes forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding expected product benefits, anticipated product approvals, future plans related to the product lines, the benefits of the transaction, including future financial and operating results, objectives and expectations and other statements that are not historical facts. Such statements are based on the views and assumptions of the management of the company and are subject to significant risks and uncertainties.
Actual future events or results may differ materially from these statements as a result of various factors, including: unexpected costs of device development and approvals, unanticipated outcomes after more expanded pre-clinical and clinical experience with the devices, unexpected changes or delays related to product supply, potentials for unexpected regulatory or quality delays or developments, competitive dynamics, global economic conditions and customer acceptance, and other economic, business, and/or competitive factors. The forward-looking statements speak only as of the date of this communication. Except as required by law, The Company undertakes no obligation to update these statements.
CoreVista is a trademark of CardioPrecision Ltd.